Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study
Publication
, Conference
Secord, AA; Soumaoro, I; Kavalerchik, E; Liu, Y; Marth, C
Published in: Gynecologic Oncology
September 2025
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
September 2025
Volume
200
Start / End Page
112 / 112
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Soumaoro, I., Kavalerchik, E., Liu, Y., & Marth, C. (2025). Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study. In Gynecologic Oncology (Vol. 200, pp. 112–112). Elsevier BV. https://doi.org/10.1016/j.ygyno.2025.04.120
Secord, Angeles Alvarez, Ibrahima Soumaoro, Edward Kavalerchik, Yan Liu, and Christian Marth. “Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study.” In Gynecologic Oncology, 200:112–112. Elsevier BV, 2025. https://doi.org/10.1016/j.ygyno.2025.04.120.
Secord AA, Soumaoro I, Kavalerchik E, Liu Y, Marth C. Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study. In: Gynecologic Oncology. Elsevier BV; 2025. p. 112–112.
Secord, Angeles Alvarez, et al. “Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study.” Gynecologic Oncology, vol. 200, Elsevier BV, 2025, pp. 112–112. Crossref, doi:10.1016/j.ygyno.2025.04.120.
Secord AA, Soumaoro I, Kavalerchik E, Liu Y, Marth C. Rinatabart sesutecan versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian cancer: A phase III, open-label, randomized study. Gynecologic Oncology. Elsevier BV; 2025. p. 112–112.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
September 2025
Volume
200
Start / End Page
112 / 112
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis